Role of adaptive and innate immune cells in chronic fatigue syndrome/myalgic encephalomyelitis

International Immunology

Volumn 26, Issue 4, 2014, Pages 233-242

  Brenu, Ekua Weba ^a,b   Huth, Teilah K ^b   Hardcastle, Sharni L ^b   Fuller, Kirsty ^b   Kaur, Manprit ^b   Johnston, Samantha ^b   Ramos, Sandra B ^b   Staines, Don R ^b,c   Marshall Gradisnik, Sonya M ^a,b  

^a GRIFFITH UNIVERSITY   (Australia)

^b GRIFFITH UNIVERSITY   (Australia)

^c QUEENSLAND HEALTH   (Australia)

Author keywords

B cells; Degranulation; Dendritic cells; NK cells; T cells

Indexed keywords

5' NUCLEOTIDASE; CD39 ANTIGEN; CELL ADHESION MOLECULE; CELL PROTEIN; GAMMA INTERFERON; GRANZYME B; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; PERFORIN; TUMOR NECROSIS FACTOR ALPHA;

ADAPTIVE IMMUNITY; ADULT; ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL SURFACE; CHRONIC FATIGUE SYNDROME; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOTOXICITY; DEGRANULATION; DENDRITIC CELL; ERYTHROCYTE SEDIMENTATION RATE; GAMMA DELTA T LYMPHOCYTE; HEMATOCRIT; HUMAN; IMMUNOCOMPETENT CELL; INNATE IMMUNITY; MEMORY CELL; MONOCYTE; NATURAL KILLER CELL; NEUTROPHIL; PHENOTYPE; PRE B LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE; THROMBOCYTE; CELL CULTURE; FEMALE; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; IMMUNOPHENOTYPING; LYMPHOCYTE SUBPOPULATION; MALE; METABOLISM; MIDDLE AGED; VIROLOGY;

ADAPTIVE IMMUNITY; B-LYMPHOCYTES; CELLS, CULTURED; CYTOTOXICITY, IMMUNOLOGIC; FATIGUE SYNDROME, CHRONIC; FEMALE; GENE EXPRESSION REGULATION; HUMANS; IMMUNITY, INNATE; IMMUNOPHENOTYPING; INTERFERON-GAMMA; KILLER CELLS, NATURAL; LYMPHOCYTE SUBSETS; MALE; MIDDLE AGED; NEUTROPHILS; T-LYMPHOCYTES, REGULATORY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84897530373     PISSN: 09538178     EISSN: 14602377     Source Type: Journal    
DOI: 10.1093/intimm/dxt068     Document Type: Article

References (80)

1. Fukuda, K., Straus, S. E., Hickie, I., Sharpe, M. C., Dobbins, J. G. and Komaroff, A. 1994. The chronic fatigue syndrome: a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group. Ann. Intern. Med. 121:953.
2. White, P. D., Goldsmith, K., Johnson, A. L., Chalder, T., Sharpe, M.,, and Group, P. T. M. 2013. Recovery from chronic fatigue syndrome after treatments given in the PACE trial. Psychol. Med. 43:2227.
3. Proal, A. D., Albert, P. J., Marshall, T. G., Blaney, G. P., and Lindseth, I. A. 2013. Immunostimulation in the treatment for chronic fatigue syndrome/myalgic encephalomyelitis. Immunol. Res. 56:398.
4. Poppe, C., Petrovic, M., Vogelaers, D., and Crombez, G. 2013. Cognitive behavior therapy in patients with chronic fatigue syndrome: the role of illness acceptance, and neuroticism. J. Psychosom. Res. 74:367.
5. Myhill, S., Booth, N. E., and McLaren-Howard, J. 2013. Targeting mitochondrial dysfunction in the treatment of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) - a clinical audit. Int. J. Clin. Exp. Med. 6:1.
6. Heins, M. J., Knoop, H., and Bleijenberg, G. 2013. The role of the therapeutic relationship in cognitive behaviour therapy for chronic fatigue syndrome. Behav. Res. Ther. 51:368.
7. Crawley, E., Collin, S. M., White, P. D. et al. 2013. Treatment outcome in adults with chronic fatigue syndrome: a prospective study in England based on the CFS/ME national outcomes database. QJM 106:555.
8. Carruthers, B. M., Jain, A. K., De Meirleir, K. L. et al. 2003. Myalgic encephalomyelitis/chronic fatigue syndrome:clinical working case definition, diagnostic, and treatment protocols. J. Chronic Fatigue 11:7.
9. Lloyd, A. R., Hickie, I., Boughton, C. R., Spencer, O., and Wakefield, D. 1990. Prevalence of chronic fatigue syndrome in an Australian population. Med. J. Aust. 153:522.
10. Sharpe, M. C., Archard, L. C., Banatvala, J. E. et al. 1991. A report--chronic fatigue syndrome: guidelines for research. J. R. Soc. Med. 84:118.
11. Brenu, E. W., Tajouri, L., Ashton, K. J., Staines, D. R.,, and Marshall-Gradisnik, S. 2013. In Stanilova, S. A., ed., Genes, and Autoimmunity - Intracellular Signaling, and Microbiome Contribution, p. 205. InTech, Croatia.
12. Brenu, E. W., Ashton, K. J., van Driel, M. et al. 2012. Cytotoxic lymphocyte microRNAs as prospective biomarkers for chronic fatigue syndrome/myalgic encephalomyelitis. J. Affect. Disord. 141:261.
13. Brenu, E. W., Staines, D. R., Baskurt, O. K. et al. 2010. Immune, and hemorheological changes in chronic fatigue syndrome. J. Transl. Med. 8:1.
14. Brenu, E. W., van Driel, M. L., Staines, D. R. et al. 2011. Immunological abnormalities as potential biomarkers in chronic fatigue syndrome/myalgic encephalomyelitis. J. Transl. Med. 9:81.
15. Corthay, A. 2009. How do regulatory T cells work? Scand. J. Immunol. 70:326.
16. Serra, P., Amrani, A., Yamanouchi, J. et al. 2003. CD40 ligation releases immature dendritic cells from the control of regulatory CD4+CD25+ T cells. Immunity 19:877.
17. Huang, Y. M., Stoyanova, N., Jin, Y. P. et al. 2001. Altered phenotype, and function of blood dendritic cells in multiple sclerosis are modulated by IFN-beta, and IL-10. Clin. Exp. Immunol. 124:306.
18. Thomas, R., and Quinn, C. 1996. Functional differentiation of dendritic cells in rheumatoid arthritis: role of CD86 in the synovium. J. Immunol. 156:3074.
19. André, S., Tough, D. F., Lacroix-Desmazes, S., Kaveri, S. V., and Bayry, J. 2009. Surveillance of antigen-presenting cells by CD4+ CD25+ regulatory T cells in autoimmunity: immunopathogenesis, and therapeutic implications. Am. J. Pathol. 174:1575.
20. Boyman, O., Conrad, C., Tonel, G., Gilliet, M., and Nestle, F. O. 2007. The pathogenic role of tissue-resident immune cells in psoriasis. Trends Immunol. 28:51.
21. Ludewig, B., Odermatt, B., Landmann, S., Hengartner, H., and Zinkernagel, R. M. 1998. Dendritic cells induce autoimmune diabetes, and maintain disease via de novo formation of local lymphoid tissue. J. Exp. Med. 188:1493.
22. Conti, L., Casetti, R., Cardone, M. et al. 2005. Reciprocal activating interaction between dendritic cells, and pamidronatestimulated gammadelta T cells: role of CD86, and inflammatory cytokines. J. Immunol. 174:252.
23. Carding, S. R., and Egan, P. J. 2002. Gammadelta T cells: functional plasticity, and heterogeneity. Nat. Rev. Immunol. 2:336.
24. Konigshofer, Y., and Chien, Y. H. 2006. Gammadelta T cells - innate immune lymphocytes? Curr. Opin. Immunol. 18:527.
25. Dupuy, P., Heslan, M., Fraitag, S., Hercend, T., Dubertret, L., and Bagot, M. 1990. T-cell receptor-gamma/delta bearing lymphocytes in normal, and inflammatory human skin. J. Invest. Dermatol. 94:764.
26. Falini, B., Flenghi, L., Pileri, S. et al. 1989. Distribution of T cells bearing different forms of the T cell receptor gamma/delta in normal, and pathological human tissues. J. Immunol. 143:2480.
27. Aljurf, M., Ezzat, A., and O Musa, M. 2002. Emerging role of gammadelta T-cells in health, and disease. Blood Rev. 16:203.
28. Viale, M., Ferrini, S., and Bacigalupo, A. 1992. TCR gamma/delta positive lymphocytes after allogeneic bone marrow transplantation. Bone Marrow Transplant. 10:249.
29. Su, D., Shen, M., Li, X., and Sun, L. 2013. Roles of gamma delta T Cells in the Pathogenesis of Autoimmune Diseases. Clin. Dev. Immunol. 2013:985753.
30. de Paoli, P., Basaglia, G., Gennari, D., and Santini, G. 1991. Gamma delta T cells in infectious diseases. Allergol. Immunopathol. 19:123.
31. Su, D. L., Lu, Z. M., Shen, M. N., Li, X., and Sun, L. Y. 2012. Roles of pro-, and anti-inflammatory cytokines in the pathogenesis of SLE. J. Biomed. Biotechnol. 2012:347141.
32. Anane, L. H., Edwards, K. M., Burns, V. E., Zanten, J. J., Drayson, M. T., and Bosch, J. A. 2010. Phenotypic characterization of gammadelta T cells mobilized in response to acute psychological stress. Brain. Behav. Immun. 24:608.
33. Henriques, A., Ines, L., Carvalheiro, T. et al. 2012. Functional characterization of peripheral blood dendritic cells, and monocytes in systemic lupus erythematosus. Rheumatol. Int. 32:863.
34. Willmann, K., Dunne, J. F. 2000. A flow cytometric immune function assay for human peripheral blood dendritic cells. J. Leukoc. Biol. 67:536
35. Brenu, E. W., van Driel, M. L., Staines, D. R. et al. 2011. Immunological abnormalities as potential biomarkers in chronic fatigue syndrome/myalgic encephalomyelitis. J. Transl. Med. 9:81.
36. Aubry, J. P., Blaecke, A., Lecoanet-Henchoz, S. et al. 1999. Annexin V used for measuring apoptosis in the early events of cellular cytotoxicity. Cytometry 37:197.
37. Aktas, E., Kucuksezer, U. C., Bilgic, S., Erten, G., and Deniz, G. 2009. Relationship between CD107a expression, and cytotoxic activity. Cel. Immunol. 254:149.
38. Alter, G., Malenfant, J. M., and Altfeld, M. 2004. CD107a as a functional marker for the identification of natural killer cell activity. J. Immunol. Methods 294:15.
39. Dickson, L., and Finlayson, K. 2009. VPAC, and PAC receptors: from ligands to function. Pharmacol. Ther. 121:294.
40. Bux, J. 2008. Human neutrophil alloantigens. Vox Sang. 94:277.
41. Göhring, K., Wolff, J., Doppl, W. et al. 2004. Neutrophil CD177 (NB1 gp, HNA-2a) expression is increased in severe bacterial infections, and polycythaemia vera. Br. J. Haematol. 126:252.
42. Stroncek, D. 2004. Granulocyte gene polymorphisms, and mutations: effects on immune response, and neutrophil proliferation. Vox Sang. 87(Suppl. 2):101.
43. Stroncek, D. F., Caruccio, L., and Bettinotti, M. 2004. CD177: a member of the Ly-6 gene superfamily involved with neutrophil proliferation, and polycythemia vera. J. Transl. Med. 2:8.
44. Stroncek, D. 2002. Neutrophil-specific antigen HNA-2a (NB1, CD177): serology, biochemistry, and molecular biology. Vox Sang. 83(Suppl. 1):359.
45. Stroncek, D. 2002. Neutrophil alloantigens. Transfus. Med. Rev. 16:67.
46. Bayat, B., Werth, S., Sachs, U. J., Newman, D. K., Newman, P. J., and Santoso, S. 2010. Neutrophil transmigration mediated by the neutrophil-specific antigen CD177 is influenced by the endothelial S536N dimorphism of platelet endothelial cell adhesion molecule- 1. J. Immunol. 184:3889.
47. Caligiuri, M. A. 2008. Human natural killer cells. Blood 112:461.
48. Wowk, M. E., and Trapani, J. A. 2004. Cytotoxic activity of the lymphocyte toxin granzyme B. Microbes Infect. 6: 752.
49. Heusel, J. W., Wesselschmidt, R. L., Shresta, S., Russell, J. H., and Ley, T. J. 1994. Cytotoxic lymphocytes require granzyme-B for the rapid induction of DNA fragmentation, and apoptosis in allogeneic target-cells. Exp. Hematol. 22:731.
50. Afonina, I. S., Cullen, S. P., and Martin, S. J. 2010. Cytotoxic, and non-cytotoxic roles of the CTL/NK protease granzyme B. Immunol. Rev. 235:105.
51. Alter, G., Rihn, S., Streeck, H. et al. 2008. Ligand-independent exhaustion of killer immunoglobulin-like receptor-positive CD8+ T cells in human immunodeficiency virus type 1 infection. J. Virol. 82:9668.
52. Agrawal, A. 2013. Mechanisms, and implications of age-associated impaired innate interferon secretion by dendritic cells: a mini-review. Gerontology 59:421.
53. Swiecki, M., Wang, Y., Vermi, W., Gilfillan, S., Schreiber, R. D., and Colonna, M. 2011. Type I interferon negatively controls plasmacytoid dendritic cell numbers in vivo. J. Exp. Med. 208:2367.
54. Badr, G., Saad, H., Waly, H. et al. 2010. Type I interferon (IFNalpha/beta) rescues B-lymphocytes from apoptosis via PI3Kdelta/Akt, Rho-A, NFkappaB, and Bcl-2/Bcl(XL). Cell. Immunol. 263:31.
55. Lever, A. M., Lewis, D. M., Bannister, B. A., Fry, M., and Berry, N. 1988. Interferon production in postviral fatigue syndrome. Lancet 2:101.
56. Fekete, A., Soos, L., Szekanecz, Z. et al. 2007. Disturbances in B-, and T-cell homeostasis in rheumatoid arthritis: suggested relationships with antigen-driven immune responses. J. Autoimmun. 29:154.
57. Korganow, A. S., Knapp, A. M., Nehme-Schuster, H. et al. 2010. Peripheral B cell abnormalities in patients with systemic lupus erythematosus in quiescent phase: decreased memory B cells, and membrane CD19 expression. J. Autoimmun. 34:426.
58. Hartung, H. P., and Kieseier, B. C. 2010. Atacicept: targeting B cells in multiple sclerosis. Ther. Adv. Neurol. Disord. 3:205.
59. Bradley, A. S., Ford, B., and Bansal, A. S. 2013. Altered functional B cell subset populations in patients with chronic fatigue syndrome compared to healthy controls. Clin. Exp. Immunol. 172:73.
60. Taylor, J. J., Jenkins, M. K., and Pape, K. A. 2012. Heterogeneity in the differentiation, and function of memory B cells. Trends Immunol. 33:590.
61. Sanz, I., Wei, C., Lee, F. E., and Anolik, J. 2008. Phenotypic, and functional heterogeneity of human memory B cells. Semin. Immunol. 20:67.
62. Wei, C., Anolik, J., Cappione, A. et al. 2007. A new population of cells lacking expression of CD27 represents a notable component of the B cell memory compartment in systemic lupus erythematosus. J. Immunol. 178:6624.
63. Anolik, J. H., Barnard, J., Cappione, A. et al. 2004. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum. 50:3580.
64. Curriu, M., Carrillo, J., Massanella, M. et al. 2013. Screening NK-, B-, and T-cell phenotype, and function in patients suffering from Chronic Fatigue Syndrome. J. Transl. Med. 11:68.
65. Deaglio, S., Dwyer, K. M., Gao, W. et al. 2007. Adenosine generation catalyzed by CD39, and CD73 expressed on regulatory T cells mediates immune suppression. J. Exp. Med. 204:1257.
66. Mandapathil, M., Hilldorfer, B., Szczepanski, M. J. et al. 2010. Generation, and accumulation of immunosuppressive adenosine by human CD4+CD25highFOXP3+ regulatory T cells. J. Biol. Chem. 285:7176.
67. Haskó, G., Linden, J., Cronstein, B., and Pacher, P. 2008. Adenosine receptors: therapeutic aspects for inflammatory, and immune diseases. Nat. Rev. Drug Discov. 7:759.
68. Fletcher, M. A., Zeng, X. R., Maher, K. et al. 2010. Biomarkers in chronic fatigue syndrome: evaluation of natural killer cell function, and dipeptidyl peptidase IV/CD26. PLoS One 5:e10817.
69. Ryba, M., and Mysliwska, J. 2010. [CD4+CD25+Foxp3+ T lymphocytes: naturally occuring regulatory T cells]. Pediatr. Endocrinol. Diabetes. Metab. 16:289.
70. Häusler, S. F., Montalbán del Barrio, I., Strohschein, J. et al. 2011. Ectonucleotidases CD39, and CD73 on OvCA cells are potent adenosine-generating enzymes responsible for adenosine receptor 2A-dependent suppression of T cell function, and NK cell cytotoxicity. Cancer Immunol. Immunother. 60:1405.
71. Jeffe, F., Stegmann, K. A., Broelsch, F., Manns, M. P., Cornberg, M., and Wedemeyer, H. 2009. Adenosine, and IFN-{alpha} synergistically increase IFN-gamma production of human NK cells. J. Leukoc. Biol. 85:452.
72. Huang, S., Apasov, S., Koshiba, M., and Sitkovsky, M. 1997. Role of A2a extracellular adenosine receptor-mediated signaling in adenosine-mediated inhibition of T-cell activation, and expansion. Blood 90:1600.
73. Lappas, C. M., Rieger, J. M., and Linden, J. 2005. A2A adenosine receptor induction inhibits IFN-gamma production in murine CD4+ T cells. J. Immunol. 174:1073.
74. MacKenzie, W. M., Hoskin, D. W., and Blay, J. 1994. Adenosine inhibits the adhesion of anti-CD3-activated killer lymphocytes to adenocarcinoma cells through an A3 receptor. Cancer Res. 54:3521.
75. MacKenzie, W. M., Hoskin, D. W., and Blay, J. 2002. Adenosine suppresses alpha(4)beta(7) integrin-mediated adhesion of T lymphocytes to colon adenocarcinoma cells. Exp. Cell Res. 276:90.
76. Raskovalova, T., Lokshin, A., Huang, X. et al. 2007. Inhibition of cytokine production, and cytotoxic activity of human antimelanoma specific CD8+, and CD4+ T lymphocytes by adenosineprotein kinase A type I signaling. Cancer Res. 67:5949.
77. Priebe, T., Platsoucas, C. D., and Nelson, J. A. 1990. Adenosine receptors, and modulation of natural killer cell activity by purine nucleosides. Cancer Res. 50:4328.
78. Romio, M., Reinbeck, B., Bongardt, S., Hüls, S., Burghoff, S., and Schrader, J. 2011. Extracellular purine metabolism, and signaling of CD73-derived adenosine in murine Treg, and Teffcells. Am. J. Physiol. Cell Physiol. 301:C530.
79. Haskó, G., and Cronstein, B. N. 2004. Adenosine: an endogenous regulator of innate immunity. Trends Immunol. 25:33.
80. Eltzschig, H. K., Macmanus, C. F., and Colgan, S. P. 2008. Neutrophils as sources of extracellular nucleotides: functional consequences at the vascular interface. Trends Cardiovasc. Med. 18:103.